In previously published data, no differences in catalysis were observed between wild type and prostate cancer‐associated mutants of ELAC2 (the missense substitution and two much more frequent polymorphisms) using nuclear‐encoded pre‐tRNA substrates (Minagawa, Takaku, Takagi, & Nashimoto, 2005; Takaku, Minagawa, Takagi, & Nashimoto, 2003; Yan and Levinger, unpublished observations). This evidence concerns the gene ELAC2 and prostate carcinoma.